Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Volasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 17/20 | 1.00 |
| ▸ | BRD4 | O60885 | 12/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 4/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 4/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 1.00 |
| ▸ | PDXK | O00764 | 2/20 | 1.00 |
| ▸ | NEK3 | P51956 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
| ▸ | WEE1 | P30291 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.64 |
| ▸ | CLK2 | P49760 | 3/20 | 0.64 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.64 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.64 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.64 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.64 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.64 |
| ▸ | PRKCG | P05129 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Volasertib SCHEMBL16984415 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL30753526 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL9888052 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL18636896 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL14136759 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL738946 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL29363620 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL18636919 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL21916558 | 1.00 | PLK1 (1.00) | PLK1BRD4PLK3PTK2BRDT | |
| Volasertib SCHEMBL29644957 | 0.99 | PLK1 (0.99) | PLK1BRD4PLK3PTK2BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101836-A1 | METHOD FOR INDUCING ANEUPLOIDY AND/OR CHROMOSOMAL INSTABILITY IN HUMAN OR NON-HUMAN PRIMATE PLURIPOTENT STEM CELLS AND DIAGNOSTIC/THERAPEUTIC USES THEREOF | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2025-05-15 | — | — | WO | claimed |
| CN-117794523-A | Cancer treatment using PARP inhibitors and PLK1 inhibitors | 凯帝夫肿瘤科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-3098223-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2016-11-30 | — | — | EP | claimed |
| US-8664222-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-04 | — | — | US | claimed |
| EP-2543669-A2 | Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation | Boehringer Ingelheim International GmbH (DE) | 2013-01-09 | — | — | EP | claimed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | claimed |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | claimed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| EP-2340837-A1 | Combination treatment of cancer comprising EGFR/HER2 inhibitors | Boehringer Ingelheim International GmbH (DE) | 2011-07-06 | — | — | EP | claimed |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | claimed |
| EP-2185559-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | claimed |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | claimed |
| WO-2009019205-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | claimed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | claimed |
| EP-1984367-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-29 | — | — | EP | claimed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | claimed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | claimed |
| WO-2007090844-A1 | TRIHYDROCHLORIDE FORMS OF A DIHYDROPTERIDINONE DERIVATIVE AND PROCESSES FOR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | WO | claimed |
| US-12622911-B2 | Methods and compositions for the treatment of pulmonary fibrosis using volasertib | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-05-12 | — | — | US | disclosed |
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035903-A1 | Storage stable perfusion solution for dihydropteridinones | QDPR, F5, F12 | PLK1 2334/4885BRD4 4860/4885PLK3 2069/4885 |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, REN, DHPS | PLK1 2489/4885BRD4 645/4885PLK3 1248/4885 |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, DHPS, DPYD | PLK1 3099/4885BRD4 2295/4885PLK3 1986/4885 |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | DHPS, PKD1, AQP4 | PLK1 2690/4885BRD4 453/4885PLK3 713/4885 |
| US-12622911-B2 | Methods and compositions for the treatment of pulmonary fibrosis using volasertib | PLK1, MMP1, DSP | PLK1 1/4885BRD4 316/4885PLK3 74/4885 |
| US-20090306101-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | EGFR, ERBB2, ERBB3 | PLK1 391/4885BRD4 1015/4885PLK3 3508/4885 |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, REN, DHPS | PLK1 2489/4885BRD4 645/4885PLK3 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.